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Vasospasm has been a long known source of delayed morbidity and mortality in aneurys-
mal subarachnoid hemorrhage patients. Delayed ischemic neurologic deficits associated
with vasospasm may account for as high as 50% of the deaths in patients who survive
the initial period after aneurysm rupture and its treatment. The diagnosis and treatment of
vasospasm has still been met with some controversy. It is clear that subarachnoid hem-
orrhage is best cared for in tertiary care centers with modern resources and access to
cerebral angiography. Ultimately, a high degree of suspicion for vasospasm must be kept
during ICU care, and any signs or symptoms must be investigated and treated immedi-
ately to avoid permanent stroke and neurologic deficit.Treatment for vasospasm can occur
through both ICU intervention and endovascular administration of intra-arterial vasodilators
and balloon angioplasty. The best outcomes are often attained when these methods are
used in conjunction.The following article reviews the literature on cerebral vasospasm and
its treatment and provides the authors’ approach to treatment of these patients.
Keywords: cerebral vasospasm, balloon angioplasty, subarachnoid hemorrhage, cerebral aneurysm, delayed
ischemic neurologic deficit
INTRODUCTION
Cerebral aneurysmal rupture leading to subarachnoid hemorrhage
is reported to occur at a rate of 5–8 per 100,000 annually, with a
peak in incidence in the fifth decade of life (1). The first peak in
morbidity and mortality comes with the aneurysmal rupture and
ensuing brain damage and hydrocephalus. Treatment with urgent
surgery if there is intraparenchymal clot, or external ventricular
drain placement to treat hydrocephalus and elevated ICP has sig-
nificantly lowered morbidity and mortality in this initial period.
Early treatment of the ruptured aneurysm by either surgical or
endovascular methods to avoid further morbidity and mortality
from re-rupture is also indicated (2, 3).
After the initial subarachnoid hemorrhage, patients are still
at risk of developing further morbidity and mortality or
delayed ischemic neurologic deficit (DIND; also referred to here
as clinically significant/symptomatic vasospasm). Symptomatic
vasospasm develops in 20–40% of subarachnoid hemorrhage
patients and is one of the least understood components in their
care (4). Strokes from vasospasm account for nearly half of
the early deaths in patients who survive the initial subarach-
noid hemorrhage and aneurysm treatment (5). Angiographic
vasospasm following aneurysmal subarachnoid hemorrhage was
first described in 1950 in the work of Reid and Johnson (6) and
published the following year (7). The recognition that develop-
ment of vasospasm may play a large role in surgical outcomes
was recognized early (8) and substantiated in 1976 with a large
series suggesting that patients fare better if surgically treated
within the first 48 h (9). The benefits of avoiding surgery dur-
ing peak risk times for vasospasm were further characterized in
the 1990s with the International Cooperative Study on the Tim-
ing of Aneurysm Surgery (10) showing that surgery during the
time of peak vasospasm leads to the worst outcomes. The devel-
opment of endovascular techniques has favorably impacted this
concept as endovascular interventions can be coupled with treat-
ment of vasospasm and do not seem to carry a worse prognosis
when performed within the high-risk period.
While the ultimate underlying mechanisms that cause
vasospasm are poorly understood, it has been established that the
risk of DIND is closely related to the size of the subarachnoid clot.
In 1980, Fisher published the landmark paper establishing a clas-
sification system for subarachnoid hemorrhage patients that was
able to predict their risk of developing DIND (11). Although still
widely used in clinical practice, the Fisher classification was based
on computed tomography performed in its infancy, but the added
risk related to increasing amounts of subarachnoid or intraventric-
ular blood has been verified by other studies (12). Other factors
such as young age, smoking, drug abuse, and pre-existing hyper-
tension have been thought to be risk factors for vasospasm, but
these have not helped much in prediction models for vasospasm
(5). It is possible that these antecedent factors may play a role in
the severity of spasm and the response to treatment.
Given that DIND is one of the leading causes of morbidity
and mortality after aneurysmal subarachnoid hemorrhage, it is
not surprising that many strategies have been proposed to effec-
tively deal with it. Thus far, some of these have proven fruitful,
while others have not. This has culminated in the publication of
The Guidelines for the Management of Aneurysmal Subarach-
noid Hemorrhage in 2009 (2). While aneurysm treatment has
continued to improve, treatment of vasospasm continues to be
the clinical event that often frustrates neurosurgeons and neuro-
critical care physicians and can easily ruin a technically brilliant
“save” in this patient population. The remainder of this chapter
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will summarize some of the strategies that have been proposed to
combat this challenging clinical entity.
DIAGNOSIS
To adequately diagnose vasospasm, one must first be careful to
differentiate between clinical and radiographic spasm. The gold
standard radiographic test for diagnosis is cerebral angiography,
however, this is an invasive and expensive test and it is not prac-
tical for daily surveillance in all cases. Up to 70% of patients
with aneurysmal SAH show constriction of the cerebral arteries
on angiography after post-bleed day 3, but only about 50% of
these patients have a neurologic deficit attributable to this arterial
distribution, and 20% of them will go on to develop infarction
(2). This brings some controversy into the algorithm that should
be used for vasospasm treatment or prophylaxis as many of the
treatments carry some degree of morbidity themselves. In our
practice, subarachnoid hemorrhage patients between day 3 and 14
who develop a new neurologic deficit not explained by rebleeding
or hydrocephalus are taken for emergent angiography. High-grade
patients with limited neurologic exam are more difficult and the
index of suspicion must be kept higher.
Transcranial Doppler technology was developed in the 1980s
for indirect measurement of vessel caliber by way of blood flow
velocity. Given that it is an indirect measure of vessel diameter, its
use is somewhat controversial and benefits are not entirely clear. In
addition, the utility can be limited by patients with extremely thick
temporal bone that limit ultrasound windows, systemic therapies
such as HHH (discussed below), which alter hemodynamics, and
inter-observer and institutional variability, which make it diffi-
cult to standardize across the general population. TCDs have been
shown to be reliable in the MCA with sensitivity of 67%, specificity
of 99%, positive predictive value of 97%, and negative predictive
value of 78% (13). These values fall off significantly when looking
at other brain vessels, again making TCDs less reliable in areas
such as the posterior circulation. In 2004, the American Academy
of Neurology conducted a systematic review of the literature and
concluded that TCDs can be used reliably to screen for the presence
of vasospasm in the MCA, but not other vessels (14). They also
suggested the following criteria for the diagnosis or exclusion of
vasospasm: flow velocity>200 or<120 cm/s, respectively, signifi-
cant increase in the flow velocities from day to day (>50 cm/s), and
Lindegaard ratio (MCA velocity/ICA velocity)>6. In our practice,
we routinely obtain daily or every-other-day transcranial Doppler
studies in these patients from the day of the bleed to post-bleed day
14 and use the values mainly to follow trends and as a warning sign.
CT angiography has also been used in some centers for the
detection of cerebral vasospasm. Several small prospective cohorts
have shown good correlation between CTA and DSA in predict-
ing vasospasm and that many unnecessary angiograms could be
avoided by using CTA as a screening test (15–17). A more recent
meta-analysis found a sensitivity and specificity for CTA of 80
and 93%, respectively (18). It has been thought that adding CT
perfusion, or another dynamic imaging modality to CTA would
significantly increase its use as a screening study for cerebral
vasospasm, but this has not necessarily been the case. One of the
difficulties has been in which parameter of CTP to follow. Over-
all, meta-analysis has found a sensitivity of 74% and specificity
of 93% of CTP in the detection of cerebral vasospasm (18). In
our practice, we do not use CTA or CTP routinely in diagnosis of
vasospasm but reserve its use for sporadic complex cases. We find
it more efficient to move the patients with new deficits or large
TCD changes directly to angiography as this is the most accurate
diagnostic tool and also gives the option of treatment. This also
serves to limit the amount of radiation and contrast the patient is
exposed to.
PREVENTION OF DIND
The first step in the reduction of morbidity and mortality from
vasospasm is prevention of DIND. Several preventive strategies
have been proposed and studied and all are used with variable
degrees of frequency in the care of subarachnoid hemorrhage
patients today. Several excellent reviews are available detailing the
trials that have been conducted (2, 19).
Treatment with oral Nimodipine, a calcium channel blocker,
has become essentially standard of care in the United States for all
patients with subarachnoid hemorrhage. This is based on the 1983
trial by Allen et al. (20) in which 13% of patients in the placebo
group suffered a severe neurologic deficit related to vasospasm
vs. 1.7% in the Nimodipine group (p< 0.03). A larger random-
ized trial was conducted in 1989 and showed reductions of 34%
in ischemic stroke and 40% in poor outcome in patients treated
with Nimodipine compared to placebo (21). It is thought, how-
ever that these results may be in some way related to cerebral
protection since there has been no demonstration of reduction
of angiographic spasm in patients on Nimodipine (2, 22). Ongo-
ing trials using different preparations of Nimodipine are ongoing.
Other agents such as nicardipine have not shown the same ben-
efits when given intravenously (23). One promising new use for
calcium channel blockers is through intrathecal administration.
No large-scale studies have been conducted but the intrathecal
administration of nicardipine has been shown in smaller stud-
ies to reduce TCD velocities within 8 h of administration (24).
Nicardipine pellets have also been developed that can prevent local
vasospasm after aneurysm clipping (25, 26). Clinical benefits of
these therapies have not yet been firmly established.
There has been much interest in the potential of statins
to reduce the morbidity and mortality of vasospasm. Statins
are thought to improve cerebral vascular reactivity through
cholesterol-dependent mechanisms. Much of this literature has
stemmed from cardiology. Several clinical trials have been con-
ducted using statins in SAH. Tseng et al. (27) found that SAH
patients randomized to pravastatin had a 32% reduction in TCD-
diagnosed vasospasm, as well as 83% reduction in vasospasm-
related DIND and 75% reduction in mortality. A meta-analysis
including this trial and the other RCTs of statin use in 158 SAH
patients showed statistically significant reduction in vasospasm
(RR= 0.73), DIND (RR= 0.38), and mortality (RR= 0.22) (28).
More recent trials have failed to show such a robust benefit (29, 30).
The idea that DIND is caused by clotting in the spastic small
cerebral vessels has led to some investigation of the merits of fib-
rinolytic agents in the treatment of SAH patients. A meta-analysis
including five prospective trials and three retrospective series with
historical controls found significant absolute risk reduction of
14.4% for DIND, 9.5% for poor GOS score, and 4.5% for death
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(31). The benefits to functional outcome, morbidity, and mortal-
ity have been offset by the high number of complications with
this therapy and it has not gained widespread acceptance in clin-
ical practice (32). This same line of thinking has led to trials
with aspirin (33), enoxaparin (34, 35), and tirilizad (36, 37), but
these therapies have not been shown to be effective in reduc-
ing vasospasm-related morbidity and mortality in subarachnoid
hemorrhage.
Magnesium has also been studied as an agent to inhibit voltage-
gated calcium channel contraction of vascular smooth muscle. The
magnesium in aneurysmal subarachnoid hemorrhage (MASH)
trial (38) randomized 283 patients to continuous IV magne-
sium infusion vs. placebo. This showed a trend toward lower
delayed cerebral infarction (RR= 0.66) and poor clinical outcome
at 3 months (RR= 0.77), but these findings failed to reach statis-
tical significance. This finding was confirmed in a second trial,
MASH-2, which also included a meta-analysis of 2047 patients,
which also showed that magnesium was not superior to placebo
for reduction of poor outcome after subarachnoid hemorrhage
(39). It is our general practice in the ICU, however, to monitor
magnesium and supplement to normal levels.
Perhaps the most promising of the new medical therapies for
vasospasm are the endothelin receptor antagonists. Endothelin I,
when bound to its receptor, is a potent activator of vascular smooth
muscle cells resulting in vasoconstriction. Several trials have been
conducted using Clazosentan (AXV-034343) (40) and TAK-044
(41) and all have shown significant decreases in angiographic
vasospasm. Perhaps the most interesting study of clazosentan
randomized 32 patients to continuous IV infusion of clazosen-
tan vs. placebo and monitored for symptomatic, angiographically
proven vasospasm (42). Patients in the placebo arm who devel-
oped vasospasm were allowed to cross over into the study group.
There was 48% relative risk reduction in symptomatic vasospasm
in the groups as designed, and 50% of the patients who crossed
over had resolution of their vasospasm when treated with the study
drug. In the intention-to-treat analysis, there was a trend toward
decreased delayed cerebral infarction with clazosentan (15 vs. 44%,
p= 0.13), but it failed to achieve statistical significance. It is
promising; however, that the endothelin receptor antagonists may
be a target not only for prevention of vasospasm, but also poten-
tially a treatment once it has already developed. While there has
been a clear trend toward decreased angiographic vasospasm in
these studies, they have failed to show a clear benefit in out-
comes and there has been a relatively high rate of pulmonary
complications, hypotension, and anemia (19).
Ultimately, the only medical strategies for prevention of
vasospasm with enough evidence to be included in the guide-
lines for SAH patients were maintenance of normal circulating
blood volume (discussed below), and oral Nimodipine. Hope-
fully this will change in the future as further randomized trials are
conducted using newer preventive therapies.
TREATMENT OF VASOSPASM
The ultimate goal in the treatment of cerebral vasospasm after
subarachnoid hemorrhage is to avoid DIND by reducing ICP, opti-
mizing the rate of cerebral oxygen demand, and improving cere-
bral blood flow. Given these goals, early aneurysm treatment and
ventriculostomy placement for patients with elevated intracranial
pressure is a necessity. Early aneurysm treatment allows the treat-
ment team to be more aggressive with further vasospasm treatment
over the course of care.
HHH-therapy (hypertension, hypervolemia, and hemodilu-
tion) has been a mainstay in the treatment of SAH patients for
many years. The idea that avoiding hypovolemia and hemocon-
centration as a mechanism to improve outcome is not novel, and
seems intuitive; nonetheless, taking an active roll in driving these
parameters has been a little more controversial. This is espe-
cially true since the detrimental effects of this therapy include
pulmonary edema, respiratory failure, cardiac failure, renal dys-
function, and exacerbation of cerebral edema. It is useful to break
this therapy into its components for further analysis.
One of the heralding signs of vasospasm is often elevated blood
pressure, with whatever is left of cerebral autoregulation attempt-
ing to increase cerebral blood flow by increasing systemic pressure.
Whether induced hypertension is useful in preventing arterial
vasospasm is another question altogether. One study showed that
induced hypertension was able to achieve higher flow in ischemic,
but not infarcted territories, despite no change in global CBF (43).
No study of induced hypertension in isolation, though, has shown
a decrease in the development of angiographic vasospasm. Thus,
it is likely that hypertension may be useful in reversing neuro-
logic deficits that develop from vasospasm, but not as a preventive
mechanism by itself (44). In our practice, we allow the patient to
auto-regulate the blood pressure to levels up to 180 or sometimes
200 systolic once the aneurysm is secured. If the patient develops
symptomatic vasospasm with a systolic blood pressure lower than
180, then we usually augment the blood pressure with vasoactive
medications.
Hypervolemia is perhaps the most controversial of the HHH
components. Many centers continue to use hypervolemia, often
dictated by the use of central venous and pulmonary artery
catheters, despite the lack of evidence that it is beneficial. One
study (45) randomized 82 patients to either hypervolemic or euv-
olemic status, which was maintained to day 14 after aneurysmal
rupture. The central venous pressures were higher in the hyperv-
olemic group, but here was no difference in cerebral blood flow or
cerebral blood volume and the incidence of vasospasm was 20% in
both groups. Another study found no difference in the incidence
of vasospasm or in clinical outcome, but the hospital costs and
complication rate were much higher in the patients treated with
hypervolemia (46). There is little doubt to the fact that hypov-
olemia is detrimental to these patients, but hypervolemia may be
detrimental as well (2). In our practice, we prefer euvolemia and
make every effort to monitor the fluid status and patient weight
closely.
Relatively little attention is given to hemodilution as a compo-
nent of HHH-therapy. Many SAH patients become hemodiluted
as a result of operative blood loss and aggressive fluid resusci-
tation. While hemodilution can increase local CBF by decreasing
blood viscosity, it does so at the expense of severe decreases in oxy-
gen delivery capacity (47). Other studies have shown that blood
transfusion is an independent risk factor for poor outcome (48),
however this finding may be the result of whatever insult caused
the need for blood transfusion. The guideline authors did not find
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FIGURE 1 | A-P angiographic images of a 58-year old woman with Hunt
and Hess grade V subarachnoid hemorrhage from ruptured dissecting
right vertebral aneurysm. Concern for vasospasm was generated from
routine transcranial Doppler testing. The patient was already maximally
medically managed so was taken for angiography. A-P images of RICA
(A), LICA (B), and basilar artery (C) showing very severe vasospasm. A-P
images of RICA (D), LICA (E), and basilar artery (F) immediately after
balloon angioplasty and administration of intra-arterial verapamil showing
resolution of the spasm in the ICA, M1, A1, and basilar artery, as well as
improvement in the more distal spasm. A-P images of the RICA (G), LICA
(H), and basilar artery (I), 6 days after original treatment showing durability
of the angioplasty treatment in the ICA, A1, M1, and basilar artery, but
recurrence of spasm in the more distal vessels. This was treated with
administration of verapamil.
sufficient evidence to make a recommendation either way (2). In
our practice, we generally keep the hematocrit around 30%, and
use clinical indicators such as tachycardia or signs of decreased
oxygen delivery as indications for transfusion.
ENDOVASCULAR MANAGEMENT OF VASOSPASM
Endovascular balloon angioplasty techniques for treatment of
cerebral vasospasm were first described in 1984 (49). The further
development of these techniques in the treatment of vasospasm is
attractive as it may improve outcomes and ameliorate the detri-
mental effects of aforementioned HHH-therapy. There is still
much controversy today, however, regarding which techniques
are best, which patients should be candidates, and the best time
to intervene. Overall, the quality of evidence for intra-arterial
therapies is low, but it has gained nearly universal acceptance
in the algorithm for SAH treatment in centers that have quality
endovascular services.
Some controversy exists as to the specific timing of endovas-
cular therapy. One randomized trial (50) has been conducted on
the use of balloon angioplasty as a prophylactic measure. Patients
treated with prophylactic balloon angioplasty had a significant
decrease in the need for urgent rescue therapy for symptomatic
vasospasm (12 vs. 26%, p= 0.03) but had no statistical difference
in the rate of cerebral infarction (23.5 vs. 31.8%, p> 0.05) or poor
outcome at 3 months (relative risk reduction 29.4%, p> 0.05).
Several studies have shown that patients had better neurologic
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improvement if the intervention (angioplasty or intra-arterial
vasodilator administration) is performed as urgently as possible
after the neurologic decline with vasospasm (51, 52). The risk
of complications must be taken into account when determining
the timing of intervention. In the prophylactic intervention study,
4/85 (4.7%) patients had vessel perforations leading to death in
three (50).
The choice of therapy is largely dictated by the presumed
pathology. If there is little angiographic spasm in the carotid
siphon or M1 segment, then intra-arterial administration of
vasodilators is the best therapy. Studies have been conducted using
many different drugs, but many are small and retrospective. In
1993, Kassell et al. (53) described the intra-arterial administration
of papaverine for the treatment of vasospasm and showed marked
angiographic improvement in 66% and clinical improvement in
33%. These findings have been replicated in other studies (54).
Papaverine was reported to be neurotoxic and resulted in neuro-
logic decline in one study (55) and is very rarely used today in favor
of calcium channel blockers. Verapamil (56, 57) and nicardipine
(58, 59) have also been used successfully by intra-arterial admin-
istration in the treatment of vasospasm. The exact protocol for
the dosing and delivery of these agents is not clear. Some prefer a
long, slow administration time, while others give the medication
as a bolus. Interestingly, it has also been described to adminis-
ter intra-arterial verapamil via an indwelling microcatheter in
the treatment of refractory vasospasm (60). This method could
easily be complicated by thromboembolic events, however. All of
these agents are vasodilators and administration should result in
increased CBF and CBV, therefore, it is recommended that ICP
be monitored during treatment (2). It is also important to mon-
itor for systemic hypotension, as this may be more detrimental
than the vasospasm itself. In our practice, we use verapamil and
nicardipine in 10 mg aliquots in each vessel. At times, if there
is no systemic hypotension it is reasonable to increase to 20
or 30 mg in divided doses if the spasm is severe. We have also
seen better and somewhat more durable results when the 10 mg
dose is infused slowly on a pump over 10–20 min, although this
method may not be possible depending on the stability of the
patient.
In the larger cerebral vessels (ICA, M1, and basilar), balloon
angioplasty has been shown to be very effective and may be more
durable. Angioplasty is not generally considered to be safe beyond
the carotid or M1 segments (50), although this thought may
change with the introduction of newer balloon catheters that are
safer in more distal segments. We use angioplasty sparingly in
the A1 segment. Overall, the current literature regarding balloon
angioplasty for vasospasm is somewhat sparse in terms of quality
data. One study compared the effectiveness of balloon angioplasty
to intra-arterial Nimodipine and found both therapies to be effec-
tive in radiographic resolution of vasospasm, but no difference
in clinical outcomes (61). The only high-quality data regarding
angioplasty for vasospasm comes from the prophylactic balloon
angioplasty trial mentioned above (50). This trial showed a signif-
icant decrease in DIND as well as need for therapeutic angioplasty,
suggesting the durability of this treatment. A few other smaller tri-
als have shown similar trends, but are significantly limited by small
sample size (62). Further clinical trials in this area are necessary
to fully investigate the benefits of balloon angioplasty for cerebral
vasospasm. In our institution, we favor balloon angioplasty when
moderate to severe vasospasm is seen in the large vessels (ICA
or M1), but we always use this in conjunction with intra-arterial
vasodilator therapy (Figure 1), to adequately treat spasm in the
more distal vessels.
CONCLUSION
Cerebral vasospasm is an important source of morbidity and
mortality in subarachnoid hemorrhage patients. Aggressive ICU
care and compulsive management style are necessary to ade-
quately manage these patients. The body of literature on cerebral
vasospasm is relatively well developed, but still subject to the rel-
ative heterogeneity and complexity of this group of patients. The
only Class I evidence regarding cerebral vasospasm used in the
publication of the AHA subarachnoid hemorrhage guidelines (2)
was that in favor of oral Nimodipine. Early aneurysm treatment,
HHH-therapy, cerebral angioplasty, and selective intra-arterial
vasodilator therapy was recommended based on Class II evidence.
Many other pharmacologic and interventional strategies are cur-
rently being investigated. There is little doubt that reduction of
DIND will go a long way in reducing the overall morbidity and
mortality of subarachnoid hemorrhage patients, and significantly
improve our ability to care for them in the future.
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